Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Erdosteine and Bepotastine Besilate
NCT02332044Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Apr 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of erdosteine and bepotastine in bronchitis, chronic obstructive pulmonary disease (COPD), allergic rhinitis (AR) and 1 more (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 24 hours and Area Under the Curve to the Last Measurable Concentration at 24 hours. Started Apr 2014; status: completed.
02
Drugs
erdosteinebepotastine
03
Conditions
bronchitischronic obstructive pulmonary disease (COPD)allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on NCT02332044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332044.